Bruls Annette 4

What Happened

• Annette Bruls, CVP, EMEACLA at Edwards Lifesciences (EW), was granted equity awards on May 7, 2026: time‑based restricted stock units (6,650 RSUs), performance‑based RSUs (target 33,700 PSUs), and stock options covering 6,650 shares. These awards have a grant price of $0 (awards, not purchases). On May 8, 2026 she had 84 shares surrendered/withheld to cover tax obligations at $82.76 per share (proceeds/value = $6,952).

Key Details

• Grant dates: May 7, 2026 (awards and options); tax withholding: May 8, 2026.
• Award amounts: 6,650 time‑based RSUs; 33,700 target performance RSUs (PSUs); 6,650 stock options. All awards show $0 acquisition price (grants).
• Tax withholding: 84 shares withheld/disposed at $82.76 each, total ≈ $6,952.
• Vesting: Time‑based RSUs and options vest beginning one year after grant in four equal annual installments (per footnotes). PSUs vest May 7, 2029 contingent on 3‑year performance (0%–200% of target).
• Shares owned after the transaction: Not specified in this Form 4 (filing states it only reflects changes in beneficial ownership).
• Filing timeliness: Form 4 filed May 8, 2026 for transactions dated May 7–8, 2026 — appears timely (no late filing indicated).

Context

• These were compensation awards (not open‑market purchases or sales). The small 84‑share disposition was a tax withholding/payment related to the awards and is routine. Performance RSUs will only convert to shares if specified performance goals are met over the three‑year performance period; options and time‑based RSUs vest over four years. This Form 4 reflects changes in beneficial ownership only and does not identify other holdings.